SCHEMBL30296125

SCHEMBL30296125

COCN(c1noc(C)c1C)S(=O)(=O)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 5/20 0.43
TSHR P16473 3/20 0.42
GAA P10253 2/20 0.39
ALDH1A1 P00352 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
MEN1 O00255 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
RECQL P46063 1/20 0.39
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
LMNA P02545 1/20 0.38
NR1H2 P55055 1/20 0.37
RORA P35398 1/20 0.37
RORC P51449 1/20 0.37
RORB Q92753 1/20 0.37
NR1H4 Q96RI1 1/20 0.37
KEAP1 Q14145 1/20 0.37
NFE2L2 Q16236 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30296047 0.83 EDNRB (0.42) GAAALDH1A1TP53
SCHEMBL6694770 0.83 EDNRA (0.40) TSHRGAAALDH1A1NPSR1MEN1
SCHEMBL29799735 0.83 EDNRA (0.40) TSHRGAAALDH1A1NPSR1MEN1
SCHEMBL26688761 0.83 EDNRA (0.40) TSHRGAAALDH1A1MEN1KMT2A
SCHEMBL29281002 0.81 TSHR (0.34) TSHRGAAALDH1A1CYP3A4CYP2C19
SCHEMBL29799844 0.81 GAA (0.35) TSHRGAAALDH1A1NPSR1MEN1
SCHEMBL29281003 0.81 GAA (0.37) TSHRGAAALDH1A1NPSR1MEN1
SCHEMBL30844549 0.78 ALPL (0.33) TSHRGAAALDH1A1KMT2AL3MBTL1
SCHEMBL24823054 0.77 NFE2L2 (0.35) TSHRCYP3A4CYP2C19NFE2L2TP53
SCHEMBL25084130 0.77 TSHR (0.31) TSHRGAAALDH1A1CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025094214-A1 Process for the preparation of 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl) benzenesulfonamide and its intermediates thereof MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) 2025-05-08 WO disclosed
US-20250051315-A1 COMPOUND, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION ALCHEMEDICINE, INC. (JP) 2025-02-13 US disclosed
EP-4458826-A1 COMPOUND, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION Alchemedicine, Inc. (JP) 2024-11-06 EP disclosed
WO-2023025277-A1 AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2023-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051315-A1 COMPOUND, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION AGTR1, AGTR2, ADRB1 NR1I2 55/4885TSHR 194/4885GAA 3895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.